News
STADA introduces bevacizumab biosimilar in Germany and the Netherlands upon regulatory approval, with several more countries to follow soon.
STADA has broadened its specialty oncology portfolio by introducing biosimilar bevacizumab upon receiving a pan-European marketing authorisation. The cancer treatment is now available to oncologists and their patients in Germany and the Netherlands, while launches in other European countries will follow soon, depending in part on national pricing and reimbursement clearance. The launches in Germany and the Netherlands come immediately after receipt of a centralized marketing authorisation from the European Commission.
STADA has brought the monoclonal antibody to market through a partnership with Spanish developer and manufacturer mAbxience, which has extensive experience supplying bevacizumab in markets such as Latin America since 2016. Under the terms of an agreement with mAbxience, STADA holds the marketing authorisation and sales and marketing rights in around 40 European countries, including all 27 European Union member states.
Condition: Colon/BC/NSCLC/RCC/Ovarian/Cervix
Type: drug